These chimeric products have an intact kinase domain but lack the TRAF3 binding domain, and thus escape cIAP-TRAF2-TRAF3-mediated proteasomal degradation and remain stabilized in MM cells20. The gene discussed is TRAF2; the disease is Miyoshi myopathy.